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Abstract
Background: The CONsolidated Standards Of Reporting Trials (CONSORT) Statement provides a minimum standard
set of items to be reported in published clinical trials; it has received widespread recognition within the biomedical
publishing community. This research aims to provide an update on the endorsement of CONSORT by high impact
medical journals.
Methods: We performed a cross-sectional examination of the online “Instructions to Authors” of 168 high impact
factor (2012) biomedical journals between July and December 2014. We assessed whether the text of the “Instructions
to Authors” mentioned the CONSORT Statement and any CONSORT extensions, and we quantified the extent and
nature of the journals’ endorsements of these. These data were described by frequencies. We also determined whether
journals mentioned trial registration and the International Committee of Medical Journal Editors (ICMJE; other than in
regards to trial registration) and whether either of these was associated with CONSORT endorsement (relative risk and
95 % confidence interval). We compared our findings to the two previous iterations of this survey (in 2003 and 2007).
We also identified the publishers of the included journals.
Results: Sixty-three percent (106/168) of the included journals mentioned CONSORT in their “Instructions to Authors.”
Forty-four endorsers (42 %) explicitly stated that authors “must” use CONSORT to prepare their trial manuscript, 38 %
required an accompanying completed CONSORT checklist as a condition of submission, and 39 % explicitly requested
the inclusion of a flow diagram with the submission. CONSORT extensions were endorsed by very few journals. One
hundred and thirty journals (77 %) mentioned ICMJE, and 106 (63 %) mentioned trial registration.
Conclusions: The endorsement of CONSORT by high impact journals has increased over time; however, specific
instructions on how CONSORT should be used by authors are inconsistent across journals and publishers. Publishers
and journals should encourage authors to use CONSORT and set clear expectations for authors about compliance with
CONSORT.
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Background
The CONsolidated Standards Of Reporting Trials
(CONSORT) guideline was first published 20 years ago.
Since that time, it has received widespread attention, in-
cluding being lauded as a twentieth century milestone in
health research methodology [1]. CONSORT is intended
for use as a guide to reporting essential components of
trial methods and findings by those preparing and
reviewing reports of randomized trials.
The uptake of CONSORT is reflected in a number of
metrics. Combined, the 1996 [2], 2001 [3], and 2010 [4]
publications of the CONSORT Statement and Explan-
ation and Elaboration documents [5, 6] have been cited
more than 12,000 times (according to Scopus, May
2015), making CONSORT among the most highly cited
biomedical publications of all time. Perhaps a more
reflective measure of CONSORT uptake, however, is the
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support from a number of major editorial organizations
(i.e., the International Committee of Medical Journal
Editors, Committee on Publication Ethics, and World
Association of Medical Editors) and its endorsement by
more than 600 biomedical journals. Endorsement of
CONSORT is typically demonstrated by a statement in a
journal’s “Instructions to Authors” indicating support for
CONSORT or a recommendation or requirement for
authors to adhere to CONSORT when submitting a
manuscript of a randomized trial for publication
consideration.
A systematic review published in 2012 determined that
journal endorsement of CONSORT was associated with
more completely reported trials, based on assessments
of more than 16,000 trials [7]. Four CONSORT checklist
items (scientific rationale, sample size, sequence gener-
ation, and allocation concealment) and a summary score
(including varying checklist items across studies report-
ing this) were significantly more likely to be reported in
trials published in endorsing journals compared to their
nonendorsing counterparts, and almost all remaining
items were more completely reported, although this
result was not statistically significant. However, reviews
of publications also show that the reporting of key items
remains well short of acceptable, with the reporting of
details of random-allocation procedures being especially
poor.
The extent to which journals are enforcing or checking
for adherence to CONSORT in submitted/published
trials is unknown and difficult to ascertain. To date, the
best and most practical way to determine a journal’s
stance on the matter of endorsement is to identify
whether journals make recommendations around
CONSORT in their “Instructions to Authors.” Two earlier
studies have characterized CONSORT’s endorsement
across high impact factor biomedical journals over time.
In 2003, 22 % of high impact factor journals endorsed
CONSORT [8]—this increased to 38 % in 2007 [9];
however both studies concluded that many journals used
ambiguous language in terms of what was meant by
endorsement.
This study provides an up-to-date assessment of the
extent and nature of CONSORT endorsement in high
impact factor journals in 2014 (the first since publication
of CONSORT 2010) and describes changes in endorse-
ment over time.
Methods
Selection of included journals
Journals were selected using the strategy adopted in the
previous studies [8, 9]. Briefly, this consisted of using
2012 impact factors (Thomson Reuters Journal Citation
Reports-Science Citation Index Expanded) to select the
top five impact factor journals for each of 33 medical
specialties and the top 15 impact factor journals in gen-
eral and internal medicine. Journals that either explicitly
indicated or were found not to publish clinical trials, as
determined after a PubMed search (or an inspection of
the journal scope when unsure), were excluded and re-
placed by the next one on the list. Journals that appeared
in more than one specialty were not replaced by another
journal but were included only once in the analysis.
Survey of the “Instructions to Authors” published by the
journals
One assessor (LS) examined the “Instructions to
Authors” on the website of each included journal and
extracted the information of interest for each journal
between July and December 2014. Specifically, we
extracted information on whether CONSORT and/or its
extensions (for abstracts [10], acupuncture trials [11],
cluster trials [12], harms outcomes [13], herbal interven-
tions [14], noninferiority and equivalence trials [15],
nonpharmacological interventions [16], patient-reported
outcomes [17], and pragmatic trials [18]) were mentioned
and, if so, assessed the following: whether CONSORT or
any extension was mentioned as a “requirement” or as a
“recommendation” or was unclear; which version of
CONSORT (1996 [2], 2001 [3, 5], 2010 [4, 6]) was
referenced, if any; and which CONSORT document
(website, Statement paper, Explanatory paper, checklist,
flow diagram, or other) was referred to, if any. If journals
“required” CONSORT as a condition of submission, we
extracted whether a flow diagram or checklist was an
explicit requirement. While we aimed to examine
endorsement of any official CONSORT extensions, we
recognize that some types of trials for which CONSORT
extensions exist (e.g., acupuncture or herbal interventions)
may be published in niche journals not included in our
sample [19]. In accordance with the original search
strategy for this study, we made no specific attempt to
identify/include such journals.
Any mention of ICMJE and reference to clinical trial
registration (“recommended” or “required”) were also
sought and extracted. Identification of the publisher of
the included journals was also sought.
Analysis
Data were summarized descriptively using frequencies.
We examined whether any mention of ICMJE and trial
registration was associated with CONSORT endorse-
ment (relative risk and 95 % confidence interval) and
summarized the journal endorsement status for publishers
with more than one journal included in our sample. We
present our data together with findings from previous
iterations of this study [8, 9], and we compared the
stability of the endorsement status for journals that ap-
peared in more than one study year.
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Results
One hundred and eighty journals were identified in
Thomson Reuters’ Journal Citation Reports database, of
which, 12 were duplicates; thus, 168 journals were
included in our sample.
CONSORT endorsement
Of the 168 journals, 106 (63 %) mentioned CONSORT
in their online “Instructions to Authors,” compared to
38 % (62/165) in 2007 and 22 % (36/166) in 2003. This
is a relative increase of 66 % since 2007 and 186 % since
2003. Eighty-nine journals were included in all 3 years of
the study; of these, 26 (29 %) became endorsers between
2003 and 2007, and 18 (20 %) endorsed CONSORT
sometime between 2007 and 2014. No journals reversed
their endorsement across the study years.
While 44 journals (42 %) required authors to use
CONSORT, and 56 journals (53 %) recommended its use,
fewer journals stated that submission of a completed
checklist (n = 38) or a flow diagram (n = 39) was required
as a condition of submission (Table 1). The 44 journals
requiring authors to use CONSORT used explicit
language, e.g. “Authors of trials must adhere to the
CONSORT reporting guidelines appropriate to their trial
design,” or “before the trial can undergo peer review,
authors must provide a completed CONSORT checklist as
a supporting file.” Journals recommending CONSORT
(n = 56) used less forceful language, e.g. “Authors should
adhere to these guidelines when drafting their manu-
script.” In six journals, CONSORT was mentioned, but
the extent of the journal’s recommendation was unclear,
e.g., “Editorial assistance includes, but is not limited to,
providing specific guidance regarding transparent report-
ing of items mentioned in pertinent reporting standards
(e.g., CONSORT, PRISMA).” Seventy-three journals
(69 %) referred to the CONSORT checklist, and 57 (54 %)
referred to the flow diagram. In addition, while we did not
set out to collect this information, we noted that several
journals informed authors of how the checklist would be
used during the peer review process; for example, “peer
reviewers will be asked to refer to these checklists when
evaluating such studies.”
The CONSORT website, which launched in 2005, was
mentioned in the “Instructions to Authors” in 46 (58 %)
of the endorsing journals in 2007 compared to being
mentioned in 84 (79 %) of the endorsers in 2014.
Eighteen (17 %) of 106 endorsing journals referenced the
most up-to-date version of CONSORT (CONSORT
2010), 11 (10 %) referenced the CONSORT 2001
Statement, and two (2 %) cited the original version of
CONSORT (1996). Indeed, among journals mentioning
CONSORT, 83 % did not reference the most current
CONSORT Statement. No endorsing journals referred
either to the 2001 or 2010 CONSORT Explanatory
documents. Seventy-five (71 %) of the endorsing journals
did not reference any CONSORT publication. Nine
journals (8 %) referred to both the website and the
CONSORT Statement. Five journals (5 %) did not refer
to any specific CONSORT document or to the website.
CONSORT extension endorsement
Only 22 of the 168 included journals (13 %) mentioned
any of the nine CONSORT extensions published at the
time of searching, of which, all except one also endorsed
CONSORT (Table 2). No journals in our sample endorsed
the CONSORT extension for acupuncture interventions
[11]. Of note, the Abstracts and Harms extensions were
explicitly incorporated into the CONSORT 2010
checklist.
ICMJE and trial registration
One hundred thirty journals (77 %) mentioned ICMJE in
their “Instructions to Authors” in 2014, a large increase
from 42 % (n = 69/165) of the journals in 2007 and 43 %
(n = 72/166) in 2003 (Table 1). One hundred seventeen
(90 %) provided a link to the ICMJE website, 40 (34 %)
of which also mentioned the most recent ICMJE
guidance [20]. While 59 (50 %) cited an older version of
the ICMJE recommendations, most (92 %) also provided
a link to the ICMJE website where the most up- to-date
documents are hosted. Four further journals (3 %) refer-
enced specific ICMJE recommendations (e.g., “ICMJE
criteria for authorship”) but provided no citation or link
to an ICMJE document. Three journals (2 %) mentioned
ICMJE but did not provide any link or reference.
Journals that referred to CONSORT were more likely to
refer to ICMJE in the “Instructions to Authors” (97/106,
92 %) than those journals not referring to CONSORT
(33/62, 53 %) (relative risk 1.72, 95 % confidence interval
[CI] 1.35 to 2.19).
Of the 168 journals in the sample, 106 (63 %)
mentioned trial registration (CONSORT 2010 checklist
item 23) in their “Instructions to Authors” (Table 1); 78
(74 %) required registration of submitted trials, 25
(24 %) recommended registration, and three made no
specific statement of support for registration. Further-
more, 27/106 journals (35 %) referred only to the ICMJE
statement about trial registration (which references at
least seven registry options) [21], 9/106 (8 %) referred
only to clinicaltrials.gov, 12/106 (11 %) referred only to
the World Health Organization Clinical Trials Platform
[22], and 41/106 (39 %) journals referred to a combin-
ation of these three. Thirteen journals (12 %) mentioned
trial registration but did not specifically mention or
provide a link to one or more trial registries. Journals
mentioning CONSORT were more likely to mention trial
registration (91/106, 86 %) than those not mentioning
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Table 1 Mentions of CONSORT, ICMJE, and trial registration in the “Instructions to Authors” from the journals1
2014 2007 2 20033
(2012 IF) (2006 IF) (2001 IF)
N = 168 (%) N = 165 (%) N = 166 (%)
CONSORT Statement 106 (63 %) 62 (38 %) 36 (22 %)
Required 44 (42 %) 23 (37 %) 8a
Recommended 56 (53 %) 39 (63 %) 26
Can’t tell* 6 (6 %) - 2
Submit with checklist 38 (36 %) 17 (27 %) nc
Submit with flow diagram 39 (37 %) nc nc
Web address 84 (79 %) 46b (58 %) 15 + 1c (44 %)
Checklist 73 (69 %) nc nc
Flow diagram 57 (54 %) nc nc
2010 Statement 18 (17 %) nr nr
2010 E&E 0 (0 %) nr nr
2001 Statement 11 (10 %) 18 (29 %) 16 (44 %)
2001 E&E 0 (0 %) 1 (2 %) 3 (8 %)
1996 Statement 2 (2 %) 6d (10 %) 9d (17 %)
No specific reference/document indicated 5 (5 %) 0 (0 %) 0 (0 %)
ICMJE 130 (77 %) 69 (42 %) 72 (43 %)
Web address 117 (90 %) 48 (70 %) 23 (40 %)
Up-to-date reference** 41 (32 %) 3 (4 %) 27 (38 %)
Obsolete reference 59 (45 %) 15 (22 %) 41 (57 %)
Other 4 (3 %) nc nc
No specific reference 3 (2 %) 6 (9 %) 4 (6 %)
Trial registration 106 (63 %) 61 (37 %) nc
Required 78 (74 %) 44 (72 %) nc
Recommended 25 (24 %) 17 (28 %) -
Can’t tell 3 (3 %) - -
ICMJE (only) 27 (25 %) 23 (38 %) nc
ClinicalTrials.gov (only) 9 (8 %) 9 (15 %) nc
WHO International Clinical Trial Portal (only) 12 (11 %) 4 (7 %) nc
Cites combination of the above 41 (39 %) 10 (16 %) -
Other registry 3 (3 %) - -
None 14 (13 %) - -
IF impact factor, CONSORT Consolidated Standards of Reporting Trials, nc not collected, nr not relevant, E&E Explanation and Elaboration, ICMJE International
Committee of Medical Journal Editors, WHO World Health Organization
1Bolded rows are the denominator for the numbers immediately following
2Data from Hopewell et al. [9]
3Data from Altman [8]
aCollapsed from Altman [8]: Required: required (3), must (5). Recommended: should (18), strongly encouraged (1), encouraged (2), recommended (2), please (2),
may wish to consider (1). Can’t tell: see (1) and no directive comment (1).
bWeb address was misspelled (n = 2)
cReference to JAMA website
dReference to an article citing the 1996 CONSORT Statement (n = 1)
*Language ambiguous
**For 2014, this was any clear reference to the “Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals”;
for 2007 and 2003 this was a > 2000 word article entitled “Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for
biomedical publication”
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CONSORT (15/62, 24 %) (relative risk 3.55; 95 % CI 2.27
to 5.55).
CONSORT endorsement across publishers of high
impact journals
The 168 included journals were published by 39 pub-
lishers, 14 of whom published more than one of the
journals. The ratio of endorsing journals to nonendor-
sing journals was inconsistent across journals (Table 3).
In our sample, only one publisher with more than five
journals included in the sample (the American Medical
Association) had all endorsing journals and no nonendor-
sing journals.
Table 2 Mention of the CONSORT extensions published before
December 2014 in “Instructions to Authors” on journal websites
2014
(2012 Impact factor)
N = 168 (%)




Submit with checklist 0






Submit with checklist 0




Submit with checklist 0




Submit with checklist 0




Submit with checklist 0




Submit with checklist 0




Submit with checklist 1
Pragmatic Trials Extension (2008) 2 (1 %)
Required 0
Recommended 2
Table 2 Mention of the CONSORT extensions published before
December 2014 in “Instructions to Authors” on journal websites
(Continued)
Can’t tell 0
Submit with checklist 0




Submit with checklist 0
Table 3 CONSORT endorsement status by publishers with more
than one journal included in the sample



















BIOMED CENTRAL 4 3:1
BMJ PUBLISHING GROUP 5 4:1
ELSEVIER 43 28:15
LIPPINCOTT WILLIAMS & WILKINS 20 15:5
MARY ANN LIEBERT 2 0:2
NATURE PUBLISHING GROUP 10 6:4
OXFORD UNIVERSITY PRESS 10 3:7
PUBLIC LIBRARY OF SCIENCE 3 3:0
SAGE PUBLICATIONS 2 2:0
SPRINGER 5 1:4
WILEY-BLACKWELL 27 15:12
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Discussion
The CONSORT Statement continues to gain traction
among the biomedical journal community. As of December
2014, CONSORT was endorsed by 63 % of high impact
journals – almost triple the number of endorsers since
the first investigation of this kind was conducted in
2003 and a 63 % (relative) increase since 2007. While
less than 20 % of the endorsing journals referenced the
most up-to-date CONSORT Statement and none re-
ferred to either of the CONSORT Explanation and
Elaboration papers, most (90 %) provide a link to the
CONSORT website, which always provides access to the
most recent CONSORT documents. Recently, we have
seen that journal endorsement of CONSORT is associ-
ated with more completely reported trials compared to
nonendorsement, based on a 2012 systematic review
including over 16,000 trials [7].
These numbers are encouraging. However, while CON-
SORT is a set of standard reporting recommendations, its
implementation is far from standardized. For example,
many of the endorsing journals in our sample did not
make strong statements about CONSORT; approximately
one half of the journals stop short of insisting that authors
follow the guideline. Approximately one quarter of the
journals ask that both a checklist and flow diagram are
included with the trial submission, one third of the
journals ask authors to submit either one or the other, and
approximately one half of the endorsing journals do not
specifically ask or require authors to submit either a
CONSORT checklist or flow diagram. Even among trials
published in endorsing journals in the aforementioned re-
view, the reporting of many CONSORT items is still poor
[7]. Undoubtedly, authors may be unaware or confused,
about journal expectations regarding author use and ad-
herence to CONSORT. This is in agreement with findings
from the aforementioned review, which indicated that
seemingly large relative effects of endorsement did not al-
ways translate into similar absolute effects [7]. For in-
stance, the review found that the description of allocation
concealment is complete in 81 % more trials published in
endorsing journals than in nonendorsing journals [7]. In
absolute terms, this equated to only 45 % of the trials in
the endorsing journals (n = 876) and 22 % of the trials
published in the nonendorsing journals (n = 1,520). Given
that allocation concealment is essential to maintaining
trial validity, the fact that it is incompletely described in
more than one half of trials is a serious concern. There-
fore, a simple statement in a journal’s “Instructions to
Authors” about using or adhering to CONSORT is likely
not sufficient on its own for improving reporting to the
extent needed for some checklist items.
Authors can and should do better. Likewise, peer
reviewers need to recognize the importance of identifying
deficiencies in reporting. A 2014 series in The Lancet
called for increased value and reduced waste in research.
The authors called on gatekeepers of the publishing and
dissemination process, including journals, to help authors
increase their awareness, capacity, and capabilities around
optimal reporting practices [23, 24]. Journals should be
assured that their efforts toward CONSORT endorsement
leading to better trial reporting are worthwhile. However,
a supporting statement in a journal’s “Instructions to
Authors” is proving insufficient to improve trial reporting
on a large scale, and more must be done. One study
compared the reporting of trial abstracts in journals with
varying levels of endorsement of the CONSORT for
abstracts extensions [25]. It found that trials published in
journals with a policy to actively implement the guideline
(e.g., to send an email to authors to revise the abstract
according to the guideline) were more completely reported
than those in journals with no active policy [25].
In Box 1, we offer some unambiguous standard
language that can be used by journals in their “Instruc-
tions to Authors” to demonstrate their support for
CONSORT and indicate their expectations of the authors.
Collectively, the biomedical publishing industry is an
important gatekeeper, determining which research reaches
healthcare professionals and, ultimately, which is incorpo-
rated into patient-care decisions. The endorsement status
of journals across publishers (Table 3) suggests that
journals with the same publisher do not necessarily share
a common set of “Instructions to Authors.” A standard
set of “Instructions to Authors” across publishers, allowing
tailored information for each journal as necessary, may
help to ensure better author understanding of journal
expectations (including those around reporting) and
facilitate an efficient peer review process by providing
consistent messaging about journal expectations. Doing
so may also benefit publishers. In this industry, the in-
exorable pursuit of impact metrics continues. Publishing
research that adheres to minimum reporting standards,
Box 1. Recommended endorsement text for journals
to include in their “Instructions to Authors”
“[Journal name] requires a completed CONSORT 2010 checklist and
flow diagram as a condition of submission when reporting the
results of a randomized trial. Templates for these can be found here
or on the CONSORT website [www.consort-statement.org], which
also describes several CONSORT checklist extensions for different
designs and types of data beyond two-group parallel trials. At
minimum, your article should report the content addressed by each
item on the checklist. Meeting these basic reporting requirements
will greatly improve the value of your trial report, may facilitate
and/or enhance the peer review process, and may enhance the
chance for eventual publication of your report."
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such as those outlined in CONSORT, will produce more
usable reports. For publishers, increasing the usability of a
report may increase its ability to be included, and there-
fore cited, in future research.
Lastly, our survey sampled journals with the highest
2012 impact factors in the medical specialties and in
general medicine. Almost all of the general medical jour-
nals included in our sample (13/15) endorse CONSORT,
and most have been involved in efforts to improve
research reporting quality and completeness over the past
two decades. Some specialties/subspecialties are now
taking on the responsibility of improving research reporting
within their specialty using a top-down approach. For
example, a 2014 editorial in the Archives of Physical Medi-
cine and Rehabilitation outlining a commitment to enforce
mandatory compliance with reporting guidelines, including
CONSORT, has been co-published by at least 35 journals,
mostly within the rehabilitation specialty. This creates a
complete “circle” of endorsing journals within a subspe-
cialty, so authors must comply if they want to publish their
research in a relevant journal [26]. This top-down model
within a subspecialty is being repeated elsewhere [27, 28].
Conclusions
Many journals now endorse the CONSORT Statement,
and such endorsement has been found to be associated
with more complete reporting. Publishers and journals
should encourage authors to use CONSORT and set clear
expectations for authors about compliance with CON-
SORT (and indeed other reporting guidelines). They should
make such information transparent and unambiguous in
their “Instructions to Authors.” Doing so will help authors
to prepare high-quality reports of randomized trials, leading
to better quality evidence to inform the treatment and
prevention of disease.
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